Application of CBX3 in preparation of medicines for diagnosing skin melanoma, predicting prognosis of skin melanoma and treating skin melanoma

By constructing CBX3 knockdown lentiviral vectors and using a variety of technical means, the complexity of diagnosis and prognosis evaluation and single treatment methods of skin melanoma were solved, and the role of CBX3 in skin melanoma was discovered and a targeted melanoma was developed. New targets for cell proliferation and migration, achieving effective diagnosis and treatment of skin melanoma.

CN118932068AActive Publication Date: 2024-11-12THE SECOND AFFILIATED HOSPITAL OF SHANTOU UNIV MEDICAL COLLEGE
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202411285723.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-13
Publication Date
2024-11-12
Estimated Expiration
2044-09-13

AI Technical Summary

Technical Problem

The complex diagnosis of skin melanoma, difficulty in assessing prognosis, single treatment methods, and the lack of effective molecular targets limit the progress of gene therapy.

Method used

By constructing CBX3 knockdown lentiviral vector, using RT-PCR, real-time quantitative PCR, immunoassay, in situ hybridization or gene chip technology to diagnose and predict skin melanoma, CBX3 as a therapeutic target, and constructing CBX3 knockdown lentiviral vector Cell infection was carried out to regulate CBX3 protein expression to inhibit the proliferation and migration of melanoma cells.

Benefits of technology

New diagnostic and prognostic methods were provided, and the role of CBX3 in skin melanoma was discovered, and the therapeutic targets for CBX3 were developed, which effectively reduced the proliferation and migration ability of melanoma cells, providing a new direction for the treatment of skin melanoma.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118932068A_ABST
    Figure CN118932068A_ABST
Patent Text Reader

Abstract

The invention discloses application of CBX3 in preparation of drugs for diagnosing skin melanoma, predicting prognosis of skin melanoma and treating skin melanoma. Knock-down of expression of CBX3 has the effect of inhibiting proliferation and migration of melanoma cells. The application has the advantages that a new target spot is provided for treating the SKCM, a new medicine for effectively treating the SKCM is expected to be screened and prepared aiming at the target spot, and a new direction is provided for effectively reducing the proliferation and migration movement ability of SKCM cells and developing the medicine for treating the SKCM.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of tumor therapeutic drugs, in particular to melanoma therapeutic drugs. Background Art

[0002] Melanoma originates from melanocytes in the epidermis, mucosa, and other tissues. Melanoma grows faster than any other solid tumor and has a higher mortality rate, with approximately 230,000 new cases and 20,000 deaths each year. Cutaneous melanoma (SKCM) is the malignant tumor with the highest mortality rate among skin cancers. Although modern diagnostic techniques such as dermoscopy have greatly improved the diagnostic accuracy of cutaneous melanoma, the diagnosis of cutaneous melanoma still faces many challenges. The diagnostic results are often highly dependent on the clinical experience and professional knowledge of doctors and are highly subjective, resulting in misdiagnosis or missed diagnosis of some melanoma cases. In addition, the complex and time-consuming diagnostic process, the difficulty of early diagnosis, and the high cost of diagnosis are also important factors that limit some patients from receiving timely examination and treatment. In clinical practice, surgery is the treatment option for most patients. However, for patients in the advanced stage, the high proliferation and metastasis rate of melanoma can easily lead to poor treatment prognosis. Gene therapy has gradually received more attention in recent years and has been reported to effectively improve patient prognosis in many diseases. However, for melanoma, there is currently a lack of effective molecular targets, which limits the research progress of gene therapy technology for melanoma. There is an urgent need for a new therapeutic target to develop treatment options that can improve patient prognosis.

[0003] Chromebox protein homolog 3 (CBX3), also known as heterochromatin protein 1γ (HP1γ), is a member of the heterochromatin protein 1 family and can silence transcription. After CBX3 is trimethylated by H3 Lys-9, the chromatin in which it resides is converted to heterochromatin-like (repressed state) and is recruited to sites of UV-induced DNA damage and double-strand breaks, thereby affecting cell growth and development. Recent studies have shown that CBX3 is involved in multiple biological processes such as cell cycle, apoptosis, and immune infiltration, thereby affecting the progression of various malignant tumors, such as liver cancer, pancreatic cancer, clear cell renal carcinoma, and breast cancer.

[0004] To date, the role of CBX3 in cutaneous melanoma (SKCM) is still unclear, and there have been no reports on the treatment of cutaneous melanoma using CBX3 as a therapeutic target. Therefore, it is of potential clinical application value to analyze the correlation between CBX3 and SKCM patients, construct CBX3 knockdown and overexpression lentiviral vectors, and further explore the role of CBX3 in SKCM cell proliferation and migration. Summary of the invention

[0005] The purpose of the present invention is to provide the use of CBX3 in the preparation of drugs for diagnosing skin melanoma, predicting the prognosis of skin melanoma and treating skin melanoma, so as to solve the problems of complex skin melanoma diagnosis technology, difficult prognosis assessment and single treatment method in the prior art.

[0006] In order to achieve the above object, the present invention adopts the following technical solutions:

[0007] Use of CBX3 in preparing products for diagnosing skin melanoma or predicting the prognosis of skin melanoma.

[0008] Furthermore, the product includes a product for diagnosing skin melanoma or predicting the prognosis of skin melanoma using RT-PCR, real-time quantitative PCR, immunoassay, in situ hybridization or gene chip technology.

[0009] The present invention also provides the use of CBX3 in preparing a drug for treating skin melanoma.

[0010] The present invention also provides a method for constructing a CBX3 knockdown lentivirus, and the construction process is: synthesizing a CBX3 interference target sequence cDNA fragment, digesting the BamHI / EcoRI site of the lentiviral vector, and then inserting the CBX3 interference target sequence cDNA fragment into the linearized lentiviral vector after digestion to obtain the CBX3 knockdown lentiviral vector; mixing the CBX3 knockdown lentiviral vector, the lentiviral packaging auxiliary vector psPAX 2 and the lentiviral packaging auxiliary vector pMD2.G with Opti-MEM and incubating them uniformly to obtain three diluted vectors; mixing Lipofectamine 2000 reagent with Opti-MEM and incubating them to obtain diluted Lipofectamine 2000; quickly mixing the three diluted vectors with the diluted Lipofectamine 2000 to form a transfection complex of the three vectors and the Lipofectamine 2000 dilution, incubating the transfection complex with cells, and then culturing the cells transfected with the CBX3 knockdown lentivirus, purifying and concentrating the cell supernatant to obtain a CBX3 knockdown lentiviral concentrated solution.

[0011] Furthermore, the forward sequence of the CBX3 interference target sequence is shown as SEQ ID NO.1, and the reverse sequence is shown as SEQ ID NO.2.

[0012] Furthermore, the A260 / A280 of the plasmid DNA extracted from the CBX3 knockdown lentiviral vector, the lentiviral packaging auxiliary vector psPAX 2, and the lentiviral packaging auxiliary vector pMD2.G were all between 1.8 and 2.0;

[0013] The cells are human embryonic kidney 293T cells;

[0014] Furthermore, in the construction process of the CBX3 knockdown lentivirus, 24 hours before transfection, the cells were digested, the cell density was adjusted to 37°C, 5% CO2 and cultured for 24 hours, 2 hours before transfection, the cell culture medium was replaced with serum-free culture medium, the FV055-CBX3 knockdown lentiviral vector, the lentiviral packaging auxiliary vector pSPAX2, and the lentiviral packaging auxiliary vector pMD2.G were mixed with Opti-MEM and incubated at room temperature for 5 minutes; the Lipofectamine 2000 reagent was gently shaken, mixed with 2.4 mL Opti-MEM, and incubated at room temperature for 5 minutes; the diluted three vectors were mixed with the diluted Lipofectamine 2000 within 5 minutes, and then incubated at room temperature for 2 minutes to form a transfection complex of the three vectors and the Lipofectamine 2000 dilution; the three vectors were mixed with Lipofectamine The transfection complex of the 2000 dilution was transferred to the culture medium containing cells and mixed evenly. After culturing at 37°C, 5% CO2 for 8 hours, the complex was washed and added with culture medium. The complex was further cultured in a 37°C, 5% CO2 incubator for 48 hours and 72 hours. The cell supernatant was collected at 48 hours and 72 hours, respectively, and the virus concentrate was purified and concentrated to obtain a long-term storage at -80°C.

[0015] Furthermore, 24 h before transfection, human embryonic kidney 293T cells in logarithmic growth phase were digested and the cell density was adjusted to 1.2×10 7cells / 20mL, inoculated in a cell culture dish at 37°C, 5% CO2, and cultured for 24 hours when the cell density reaches 70%-80% for transfection; 2 hours before transfection, replace the cell culture medium with serum-free medium; mix 10μg of FV055-CBX3 knockdown lentiviral vector, 10μg of lentiviral packaging auxiliary vector pSPAX2, and 10μg of lentiviral packaging auxiliary vector pMD2.G with the corresponding volume of Opti-MEM, adjust the total volume to 2.5mL, and incubate at room temperature for 5 minutes; mix 100μL of Lipofectamine 2000 reagent with 2.4mL Opti-MEM, and incubate at room temperature for 5 minutes; gently invert and mix the diluted three vectors and the diluted Lipofectamine 2000 within 5 minutes, without shaking during the period; after mixing, incubate at room temperature for 2 minutes to form a transfection complex of the three vectors and the Lipofectamine2000 dilution; The transfection complex of the 2000 dilution was transferred to the culture medium containing 293T cells and mixed. After culturing at 37°C and 5% CO2 for 8 hours, the culture medium containing the transfection complex was discarded and washed; 25 mL of cell culture medium containing 10% serum was added to each bottle of cells, and the cells were continued to be cultured in an incubator at 37°C and 5% CO2 for 48 hours; the supernatant of 293T cells was collected and centrifuged at 4000g for 10 minutes at 4°C to remove cell debris; the supernatant was filtered through a 0.45μm filter in a 40mL ultracentrifuge tube and centrifuged at 4000×g to the required virus concentration volume; the CBX3 knockdown lentivirus in the filter cup was transferred to the sample collection cup to obtain the virus concentrate of the CBX3 knockdown lentivirus, and the virus concentrate was stored at -80°C for a long time.

[0016] The present invention also provides a CBX3 knockdown lentivirus obtained by the construction method.

[0017] The present invention also provides a use of the CBX3 knockdown lentivirus in preparing a drug for treating skin melanoma.

[0018] The advantages of the present invention include: providing a new target for treating SKCM, and it is expected that new drugs that are effective in treating SKCM can be screened and prepared based on the target, effectively reducing the proliferation and migration ability of SKCM cells, and providing a new direction for developing drugs to treat SKCM. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] The drawings described herein are used to provide a further understanding of the present invention, constitute a part of the present application, and do not constitute an improper limitation of the present invention. In the drawings:

[0020] Figure 1 The statistical graph of CBX3 expression detected by immunohistochemical staining in 192 samples;

[0021] Figure 2 This is a statistical chart showing that sequencing data results indicate that CBX3 expression is higher in tumor tissues;

[0022] Figure 3 This is the statistical graph of the overall survival time of patients in the CBX3 high expression group;

[0023] Figure 4 This is the Western blot result of CBX3 expression in different melanoma tumor cells;

[0024] Figure 5 is the DNA map of the FV055-CBX3 knockdown lentiviral vector;

[0025] Figure 6 is the DNA map of PDS407_pL-CMV-RFP-puro-CBX3 overexpression lentiviral vector;

[0026] Figure 7 is the auxiliary vector psPAX 2 plasmid DNA map;

[0027] Figure 8 is the auxiliary vector pMD2.G plasmid DNA map;

[0028] Fig. 9 It is the experimental graph of CBX3 protein expression level in cells of CBX3-sh, CBX3-nc and CBX3-oe groups;

[0029] Fig.10 This is a statistical graph showing that CCK-8 experiments prove that CBX3 has the ability to regulate SKCM cell proliferation;

[0030] Fig.11 This is an experimental diagram showing that CBX3 has the ability to regulate the proliferation of SKCM cells through a clone formation experiment;

[0031] Fig.12 This is an experimental picture showing the ability of CBX3 to regulate SKCM cell migration using a scratch test;

[0032] Fig.13 This is a diagram showing the Transwell experiment demonstrating that CBX3 has the ability to regulate SKCM cell migration;

[0033] Fig.14 This is an experimental diagram of a xenograft tumor experiment that proves that knocking down CBX3 inhibits the proliferation ability of SKCM cells in vivo;

[0034] Fig.15 This is an experimental diagram showing the ability of xenograft tumor experiments to prove that overexpression of CBX3 promotes the proliferation of SKCM cells in vivo. DETAILED DESCRIPTION

[0035] The present invention will be described in detail below in conjunction with the accompanying drawings and specific embodiments. The exemplary embodiments and descriptions of the present invention are used to explain the present invention, but are not intended to limit the present invention.

[0036] 1. Expression of CBX3 in cutaneous melanoma and its relationship with prognosis

[0037] Tissue microarrays purchased from Alenabio contained 204 skin tissue samples, and each skin tissue sample was processed with anti-CBX3 antibody (1:400; catalog number: 11650-2-AP, Wuhan Sanying Biotechnology Co., Ltd., Wuhan, China) according to the manufacturer's instructions. Twelve samples were detached and excluded, and the remaining 192 samples were subjected to immunohistochemical staining to detect CBX3 expression. SKCM-related transcriptome data included in TCGA and GTEx were downloaded from the UCSC Xena website, and two melanoma-related datasets (GSE133713 and GSE19234) were downloaded from the GEO database for exploration, visualization, and analysis of cancer genomics data. Three SKCM cell lines, A2058, A375, and Mewo (Cell Bank of the Chinese Academy of Sciences), were cultured in a humidified environment at 37°C, 5% CO2, and 95% air, and the expression of CBX3 in the cell lines was determined by Western blot.

[0038] like Figure 1 As shown in Figure 2, the expression of CBX3 was increased in most skin melanoma tissues (166 / 176), but not in most normal skin tissues (14 / 16), and the difference was statistically significant. Figure 2 As shown, Figure 1 The results shown were also verified in the sequencing data collected in the TCGA database. Tumor tissues collected in TCGA, GSE133713, and GSE19234 were grouped according to the expression level of CBX3. Figure 3 As shown in Figure 2, the prognostic analysis results suggest that the overall survival time of patients in the CBX3 high expression group is shorter. Figure 4 As shown in the figure, CBX3 was expressed most highly in the A375 cell line and least highly in the A2058 cell line. Based on the experimental results, we knocked down or overexpressed the CBX3 gene in the three cell lines in subsequent experiments.

[0039] 2. Construction of CBX3 knockdown lentiviral vector and CBX3 overexpression lentiviral vector

[0040] The CBX3 gene sequence was obtained from the National Center for Biotechnology Information (NCBI) website, see Table 1, and related overexpression and knockdown sequences were designed based on the sequence.

[0041] Table 1CBX3 cDNA gene sequence

[0042]

[0043] Hanbio Biotech (Shanghai) Co., Ltd. was commissioned to construct a CBX3 knockdown lentiviral vector. The general construction process was as follows: according to the CBX3 sequence shown in Table 1, a CBX3 interference target sequence cDNA fragment was artificially synthesized in vitro. The interference target sequence is shown in Table 2. The BamHI / EcoRI site of the lentiviral vector FV055 was digested, and then the CBX3 interference target sequence cDNA fragment was inserted into the linearized lentiviral vector FV055 after digestion to obtain a CBX3 knockdown lentiviral vector, namely, FV055-CBX3 knockdown lentiviral vector. The map is shown in Figure 5 The MCS region of the FV055-CBX3 knockdown lentiviral vector was sequenced and aligned, and the clone with the correct alignment was the successfully constructed lentiviral expression vector containing the CBX3 interference target sequence.

[0044] Table 2 CBX3 interference target sequences

[0045]

[0046] We commissioned Qingke Biotechnology Co., Ltd. to construct a CBX3 overexpression lentiviral vector. The general construction process is: digest the NheI / AscI site of the lentiviral vector PDS407_pL-CMV-RFP-puro, insert the CBX3 full-length cDNA product into the linearized lentiviral vector PDS407_pL-CMV-RFP-puro, and obtain the PDS407_pL-CMV-RFP-puro-CBX3 overexpression lentiviral vector. A PCR identification experiment was performed on the CBX3 sequence in the PDS407_pL-CMV-RFP-puro-CBX3 overexpression lentiviral vector. The primer sequences are shown in Table 3 and the results are shown in Table 4. The DNA map of the PDS407_pL-CMV-RFP-puro-CBX3 overexpression lentiviral vector is shown in Figure 6 The clones identified as positive by PCR were sequenced and compared. The clones with correct comparison were the successfully constructed overexpression lentiviral vectors containing the CBX3 gene sequence.

[0047] Table 3 CBX3 cDNA PCR amplification primers

[0048]

[0049] Table 4 PCR identification results of CBX3 gene sequence in PDS407_pL-CMV-RFP-ccdB-puro lentiviral overexpression vector

[0050]

[0051]

[0052] 3. Construction of CBX3 knockdown lentivirus, CBX3 overexpression lentivirus and negative control lentivirus

[0053] Prepare the lentiviral vector, lentiviral packaging auxiliary vector psPAX 2 and lentiviral packaging auxiliary vector pMD2.G in advance. The DNA map of the lentiviral packaging auxiliary vector psPAX 2 is as follows: Figure 7 As shown, the DNA map of the lentiviral packaging auxiliary vector pMD2.G is as follows Figure 8 The above vector plasmid DNA was extracted and dissolved in sterilized TE, and its concentration and purity were determined by ultraviolet absorption method to ensure that the A260 / A280 of the extracted plasmid DNA was between 1.8 and 2.0. If it reached this standard, it was qualified and could be used for subsequent transfection of cells.

[0054] 24 h before transfection, human embryonic kidney 293T cells in logarithmic growth phase were digested and the cell density was adjusted to 1.2×10 7Cells / 20mL, inoculated in a cell culture dish at 37°C, 5% CO2, and cultured for 24 hours when the cell density reaches 70% to 80%, it can be used for transfection. Replace the cell culture medium with serum-free medium 2 hours before transfection. Add 10μg of the prepared FV055-CBX3 knockdown lentiviral vector DNA or PDS407_pL-CMV-RFP-puro-CBX3 overexpression lentiviral vector, as well as 10μg of lentiviral packaging auxiliary vector pSPAX2 and 10μg of lentiviral packaging auxiliary vector pMD2.G to a sterile centrifuge tube, mix evenly with the corresponding volume of Opti-MEM, adjust the total volume to 2.5mL, and incubate at room temperature for 5 minutes. Gently shake the Lipofectamine 2000 reagent, take 100μL and mix it with 2.4mL Opti-MEM in another tube, and incubate at room temperature for 5 minutes. Mix the diluted three vectors with the diluted Lipofectamine 2000, gently invert and mix, do not shake, and mix within 5 minutes. After mixing, incubate at room temperature for 2 minutes to form a transfection complex of the three vectors and the Lipofectamine 2000 dilution. Transfer the transfection complex of the three vectors and the Lipofectamine 2000 dilution to the culture medium containing 293T cells, mix well, and culture at 37°C, 5% CO2. After continuing to culture for 8 hours, pour out the culture medium containing the transfection complex, wash the remaining transfection complex with PBS solution, and then pour it out. 25 mL of cell culture medium containing 10% serum was added to each bottle of cells, and the cells were cultured in a 37°C, 5% CO2 incubator for 48 h. The 293T cell supernatant was collected and replaced with fresh complete culture medium for 72 h. The 293T cell supernatant was collected again, and the supernatants of the 293T cells collected twice were centrifuged at 4°C, 4000 g for 10 min to remove cell debris; the supernatant was filtered through a 0.45 μm filter into a 40 mL ultracentrifuge tube, and centrifuged at 4000 × g to the required virus concentration volume to obtain the virus concentrate of CBX3 knockdown lentivirus or CBX3 overexpression lentivirus, and the virus biological titer was determined, and the virus concentrate was stored at -80°C for a long time. The negative control virus was constructed by using the same method but with FV055 empty vector and PDS407_pL-CMV-RFP-puro empty vector instead of FV055-CBX3 knockdown lentiviral vector and PDS407_pL-CMV-RFP-puro-CBX3 overexpression lentiviral vector.

[0055] 4. Infection of skin melanoma cell lines with CBX3 knockdown lentivirus and CBX3 overexpression lentivirus

[0056] SKCM cells in the logarithmic growth phase were digested with trypsin to a cell density of about 5 × 10 4The suspension of cells / mL was inoculated in a 6-well plate and cultured until the cell confluence reached about 50%.

[0057] Knockdown experiment: According to the multiplicity of infection (MOI) value, the MOI of CBX3 knockdown lentivirus was 6.0, and the MOI of negative control lentivirus was 2.5. Appropriate amount of CBX3 knockdown lentivirus was added to A375 and Mewo, respectively, and the medium was changed after 12 hours of culture. After 48 hours of infection, the expression of the reporter gene GFP (green fluorescent protein) on the lentivirus was observed, and the infection fluorescence rate was greater than 80%. In the control group, the CBX3 knockdown lentivirus was replaced with the negative control, and the lentivirus was experimented in the same way. SKCM cells infected with CBX3 knockdown lentivirus and negative control virus were called CBX3-sh and CBX3-nc (A375-sh / A375-nc, Mewo-sh / Mewo-nc), respectively.

[0058] Overexpression experiment: According to the multiplicity of infection (MOI) value, the MOI of CBX3 overexpression lentivirus was 8.0, and the MOI of negative control lentivirus was 3.0. An appropriate amount of CBX3 overexpression lentivirus was added to A2058, and the medium was changed after 12 hours of culture. The expression of the reporter gene RFP (red fluorescent protein) on the lentivirus was observed 48 hours after infection, and the infection fluorescence rate was greater than 80%. In the control group, the CBX3 overexpression lentivirus was replaced with the negative control lentivirus and the experiment was performed in the same way. The SKCM cells infected with CBX3 overexpression lentivirus and negative control lentivirus were called CBX3-oe and CBX3-nc (A2058-oe / A2058-nc), respectively.

[0059] 5. Western blot detection of CBX3 protein knockdown / overexpression

[0060] Proteins from CBX3-sh, CBX3-nc and CBX3-oe cells were extracted; the extracted proteins were quantified according to the instructions of the BCA kit; Image J was used for quantitative analysis to record the differences in protein expression in each group. Fig. 9 As shown, it can be seen that the relative expression level of CBX3 protein in the CBX3-sh group was significantly downregulated compared with the corresponding CBX3-nc group, and the relative expression level of CBX3 protein in the CBX3-oe group was significantly increased compared with the corresponding CBX3-nc group, proving that CBX3 protein was successfully knocked down / overexpressed.

[0061] 6. Effects of CBX3 knockdown / overexpression on the proliferation of skin melanoma cells

[0062] CCK-8 experiment: Prepare a 96-well plate, digest the logarithmic growth phase SKCM cells CBX3-sh, CBX3-nc, CBX3-oe, and CBX3-nc, centrifuge and resuspend them, take 10 μL of the cell suspension and mix it with 10 μL of trypan blue dye, take 10 μL of the mixture to count and record the cell concentration. Depending on the cell growth status, 2-5×10 3 Cells, keep the cell amount of each group the same, and add culture medium to 100μL. Set up 27 replicate wells for each group of cells and culture them in a 37℃, 5% CO2 incubator. Select three replicate wells at 0h, 12h, 24h, 36h, 48h, 60h, 72h, 84h, and 96h to add 10μL CCK8 solution. After incubation in the incubator for 2h, use a Bio-Tek microplate reader to detect the absorbance at OD450, and calculate the proliferation effect according to the formula.

[0063] Clone formation experiment: Gently pipette and mix the counted CBX3-sh, CBX3-nc, CBX3-oe, and CBX3-nc cells, add 600 cells to each well of a 6-well plate, add culture medium to 1 mL, and culture in an incubator for 14 days, changing the medium every 2-3 days. Fix the cells with 4% paraformaldehyde and 0.5% crystal violet, take pictures with a camera, and count and analyze using Image J software.

[0064] According to the results of CCK-8 experiment and clone formation experiment, Figure 10-11 As shown, the proliferation rate of cells in the CBX3-sh group was significantly lower than that in the CBX3-nc group, and the proliferation rate of cells in the CBX3-oe group was significantly higher than that in the CBX3-nc group, demonstrating that CBX3 has the ability to regulate the proliferation of SKCM cells, and CBX3 knockdown inhibits the proliferation of SKCM cells.

[0065] 7. Effects of CBX3 knockdown / overexpression on the migration ability of SKCM cells

[0066] Scratch test: Take SKCM cells CBX3-sh, CBX3-nc, CBX3-oe, and CBX3-nc in the logarithmic growth phase, digest and centrifuge, resuspend the cells in serum-free culture medium, take 10 μL, stain with trypan blue, and count. Add 2-5×10 3 Cells were added to keep the cell amount in each group the same and the culture medium was supplemented to 1 mL. Cultured in 6-well plates in serum-free medium for 12 h. Scratches were made using a sterile pipette tip. Cells were washed with PBS and cultured in medium supplemented with 2% fetal bovine serum. Micrographs of designated areas were obtained after 0 and 24 h of culture and statistically analyzed.

[0067] Transwell assay: adjust the number of cells per chamber to 3-8×10 5Culture in a 37°C, 5% CO2 incubator for 24-72 hours. Terminate the culture before the end of a cell growth cycle and remove the culture medium. Wash the upper and lower layers of the chamber with PBS, fix with a fixative (4% paraformaldehyde or a mixture of methanol and glacial acetic acid 1:3), and wash with PBS. Add crystal violet staining solution to the upper and lower layers of the chamber to immerse the cells for staining. Wipe off the cells on the upper layer of the chamber that have not passed through the chamber holes, and remove excess staining solution from the chamber. After the chamber is air-dried or immersed in water, use a microscope to take pictures of each group and record them for subsequent statistical analysis.

[0068] The results are as follows Figure 12-13 As shown, the migration speed of cells in the CBX3 knockdown group was significantly decreased, and the migration speed of cells in the CBX3 overexpression group was accelerated. It can be seen that CBX3 knockdown inhibits the migration of SKCM cells.

[0069] 8. Subcutaneous transplantation tumor experiment in nude mice verifies the effect of CBX3 knockdown / overexpression on SKCM cell proliferation

[0070] Cells A375-sh, A375-nc, A2058-oe, and A2058-nc were cultured at 2×10 6 The xenograft model was established by subcutaneously injecting BALB / c nude mice (Hunan SJA Laboratory Animal Co., Ltd., Changsha, China) at a dose of 10 cells / mouse. The cells were monitored every 4 days and the expression of the formula (width) was calculated using a sliding caliper. 2 × length) / 2 to measure the tumor volume. Four weeks after implantation, the mice were euthanized, and the subcutaneous tumor tissue was surgically removed to measure the tumor diameter and weight in different groups. Fig.14 The results showed that in animals implanted with CBX3-sh A375 cells, the growth rate and tumor weight of melanoma were significantly lower than those in the control group. Fig.15 As shown, upregulating the expression of CBX3 in A2058 cells increased the volume and weight of the tumor compared with the control group, and CBX3 knockdown inhibited the growth of melanoma cells.

[0071] The present invention constructs a CBX3 gene knockdown lentiviral vector to efficiently infect SKCM cells and significantly downregulate the expression of the CBX3 gene in the latter, and verifies at the cellular level that knocking down CBX3 has the effect of inhibiting the proliferation and migration of melanoma cells. The present invention constructs an in vivo tumor mouse animal model and verifies in vivo that knocking down CBX3 inhibits the proliferation of melanoma cells in vivo.

[0072] The technical solutions provided by the embodiments of the present invention are introduced in detail above. Specific examples are used herein to illustrate the principles and implementation methods of the embodiments of the present invention. The description of the above embodiments is only applicable to help understand the principles of the embodiments of the present invention. At the same time, for those skilled in the art, according to the embodiments of the present invention, there will be changes in the specific implementation methods and application scopes. In summary, the content of this specification should not be understood as limiting the present invention.

Claims

1. Application of CBX3 in the preparation of products for diagnosing skin melanoma or predicting the prognosis of skin melanoma.

2. The use according to claim 1, characterized in that: The products include products for diagnosing skin melanoma or predicting the prognosis of skin melanoma using RT-PCR, real-time quantitative PCR, immunodetection, in situ hybridization or gene chip technology.

3. Application of CBX3 in the preparation of drugs for the treatment of cutaneous melanoma.

4. A method for constructing a CBX3 knockdown lentivirus, characterized in that: The construction process is as follows: synthesizing a CBX3 interference target sequence cDNA fragment, digesting the BamHI / EcoRI site of the lentiviral vector, and then inserting the CBX3 interference target sequence cDNA fragment into the linearized lentiviral vector after digestion to obtain a CBX3 knockdown lentiviral vector; mixing the CBX3 knockdown lentiviral vector, the lentiviral packaging auxiliary vector psPAX 2 and the lentiviral packaging auxiliary vector pMD2.G with Opti-MEM and incubating them evenly to obtain three diluted vectors; mixing the Lipofectamine 2000 reagent with Opti-MEM and incubating them to obtain diluted Lipofectamine 2000; quickly mixing the three diluted vectors with the diluted Lipofectamine 2000 to form a transfection complex of the three vectors and the Lipofectamine 2000 dilution, incubating the transfection complex with cells, and then culturing the cells transfected with the CBX3 knockdown lentivirus, purifying and concentrating the cell supernatant to obtain a CBX3 knockdown lentiviral concentrate.

5. The method for constructing a CBX3 knockdown lentivirus according to claim 4, characterized in that: The forward sequence of the CBX3 interference target sequence is shown in SEQ ID NO.1, and the reverse sequence is shown in SEQ ID NO.

2.

6. The method for constructing a CBX3 knockdown lentivirus according to claim 4, characterized in that: The A260 / A280 of the plasmid DNA extracted from the CBX3 knockdown lentiviral vector, the lentiviral packaging auxiliary vector psPAX 2, and the lentiviral packaging auxiliary vector pMD2.G were all between 1.8 and 2.0; The cells are human embryonic kidney 293T cells.

7. The method for constructing a CBX3 knockdown lentivirus according to claim 4, characterized in that: During the construction of the CBX3 knockdown lentivirus, 24 hours before transfection, the cells were digested, the cell density was adjusted and cultured at 37°C, 5% CO2 for 24 hours, 2 hours before transfection, the cell culture medium was replaced with a serum-free culture medium, the FV055-CBX3 knockdown lentiviral vector, the lentiviral packaging auxiliary vector pSPAX2, and the lentiviral packaging auxiliary vector pMD2.G were mixed with Opti-MEM and incubated at room temperature for 5 minutes; the Lipofectamine 2000 reagent was gently shaken, mixed with 2.4 mL Opti-MEM, and incubated at room temperature for 5 minutes; the three diluted vectors were mixed with the diluted Lipofectamine 2000 within 5 minutes, and then incubated at room temperature for 2 minutes to form a transfection complex of the three vectors and the Lipofectamine 2000 dilution; the three vectors were mixed with the Lipofectamine The transfection complex of the 2000 dilution was transferred to the culture medium containing cells and mixed evenly. After culturing at 37°C, 5% CO2 for 8 hours, the complex was washed and added with culture medium. The complex was further cultured in a 37°C, 5% CO2 incubator for 48 hours and 72 hours. The cell supernatant was collected at 48 hours and 72 hours, respectively, and the virus concentrate was purified and concentrated to obtain a long-term storage at -80°C.

8. The method for constructing a CBX3 knockdown lentivirus according to claim 7, characterized in that: 24 h before transfection, human embryonic kidney 293T cells in logarithmic growth phase were digested and the cell density was adjusted to 1.2×10 7 cells / 20mL, inoculated in a cell culture dish at 37°C, 5% CO2, and cultured for 24 hours when the cell density reaches 70%-80% before transfection; 2 hours before transfection, the cell culture medium was replaced with serum-free medium; 10μg of FV055-CBX3 knockdown lentiviral vector, 10μg of lentiviral packaging auxiliary vector pSPAX2, and 10μg of lentiviral packaging auxiliary vector pMD2.G were mixed evenly with the corresponding volume of Opti-MEM, and the total volume was adjusted to 2.5mL, and incubated at room temperature for 5 minutes; 100μL of Lipofectamine2000 reagent was mixed with 2.4mL Opti-MEM, and incubated at room temperature for 5 minutes; the diluted three vectors and the diluted Lipofectamine 2000 were gently inverted and mixed within 5 minutes, and no shaking was done during the period; after mixing, incubated at room temperature for 2 minutes to form a transfection complex of the three vectors and the Lipofectamine 2000 dilution; the three vectors were mixed with Lipofectamine The transfection complex of the 2000 dilution was transferred to the culture medium containing 293T cells and mixed evenly. After culturing at 37°C and 5% CO2 for 8 hours, the culture medium containing the transfection complex was discarded and washed. 25 mL of cell culture medium containing 10% serum was added to each bottle of cells, and the cells were further cultured in a 37°C and 5% CO2 incubator for 48 hours. The supernatant of 293T cells was collected and centrifuged at 4°C and 4000g for 10 minutes to remove cell debris. The supernatant was filtered through a 0.45 μm filter into a 40 mL ultracentrifuge tube and centrifuged at 4000 × g to the required virus concentration volume; the CBX3 knockdown lentivirus in the filter cup was transferred to the sample collection cup to obtain a virus concentrate of the CBX3 knockdown lentivirus, and the virus concentrate was stored at -80°C for a long term.

9. A CBX3 knockdown lentivirus obtained by the construction method according to any one of claims 4 to 8.

10. Use of the CBX3 knockdown lentivirus according to claim 9 in the preparation of a drug for treating skin melanoma.

Citation Information

Patent Citations

  • Method for silencing IFNARI gene in DF-1 cell line

    CN104694576A

  • VEGFA (vascular endothelial growth factor A)-gene-targeted RNA interference-based recombinant lentiviral vector and construction method thereof

    CN106480098A

  • Application of GPR143 as target spot in preparation of medicine for preventing and treating skin melanoma

    CN117987542A